Clinical Trials Logo

Clinical Trial Summary

This clinical trial evaluates the side effects and possible benefits of operating on brain tumors prior to the tumor coming back (recurrence). Understanding when surgery is most useful to patients with brain tumors is important. Some patients may undergo chemotherapy or radiation but still have visible tumor remaining after treatment. The purpose of this research is to compare outcomes of those who have surgery after chemotherapy or radiation, but prior to tumor recurrence, to those who have surgery at a different time, or no surgery at all.


Clinical Trial Description

PRIMARY OBJECTIVE: I. To evaluate the safety and feasibility of surgical resection for pre-recurrent brain tumors. SECONDARY OBJECTIVES: I. To determine whether there are differences in overall survival for patients who receive radiation therapy (RT) prior to surgery as compared to patients who receive RT after surgery or patients undergoing no further surgery. II. To determine for patients having pre-recurrent surgery whether there is a longer interval to local/regional progression, any central nervous system (CNS) progression or need for subsequent intracranial treatment compared to patients receiving post-operative RT, time to each will be separately documented. III. To determine for patients with pre-operative as compared to post-operative fractionated radiation for brain metastases (mets) whether there is a decreased rate of local recurrence. IV. To determine for patients with pre-operative as compared to post-operative fractionated radiation for brain mets whether there is a decreased rate of leptomeningeal disease. CORRELATIVE RESEARCH OBJECTIVES: I. To determine the genetic and molecular alterations occurring in radiated brain and radiated tumor tissue compared to nonradiated tissue specimens (subjects will be matched to Mayo Clinic Cancer Center Neuro-Oncology Program Registry for the study of Nervous System Tumors 12-003458). II. To investigate the relative sensitivity of radiated human CNS tumors to senolytic or other therapies in ex vivo assays targeting radiation-induced biology to promote synthetic lethality using cryopreserved or fresh tissue. III. To investigate the availability and utility of candidate biomarkers reflective of tumor burden and therapeutic susceptibility, from tissue, cerebrospinal fluid (CSF) and peripheral blood. IV. Patients self-reported outcomes may be obtained through the Neurosurgery Registry program. As available, these data may be referenced as a screening tool for any impact on quality of life (QOL) associated with trial participation as compared to matched controls. OUTLINE: Patients undergo surgery as indicated clinically when applicable. After completion of surgery, patients are followed up at 3 and 6 months, and then every 6 months thereafter. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04810871
Study type Interventional
Source Mayo Clinic
Contact
Status Recruiting
Phase N/A
Start date May 6, 2021
Completion date March 1, 2026

See also
  Status Clinical Trial Phase
Completed NCT00001972 - PET Scan of Brain Metabolism in Relation to Age and Disease N/A
Completed NCT02798406 - Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects Phase 2
Terminated NCT02855086 - Cetuximab-IRDye 800CW in Detecting Tumors in Patients With Malignant Glioma Undergoing Surgery Phase 1/Phase 2
Terminated NCT00638963 - Temozolomide as a Prophylaxis Against Brain Recurrence in Participants With Metastatic Breast Cancer (P05225 AM2) Phase 2
Withdrawn NCT03234309 - Ferumoxytol in Magnetic Resonance Imaging of Pediatric Patients With Brain Tumors Phase 2
Completed NCT00178295 - Radiation-Induced Cytokine Cascades and Their Correlation With Central Nervous System Injury N/A
Recruiting NCT02800486 - Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA Phase 2
Completed NCT01621295 - Assessing the Patient Experience in Cancer Care N/A
Completed NCT02964416 - Single Dose Tramadol Effect on Extubation Response and Quality of Emergence Post-supratentorial Intracranial Surgery Phase 4
Completed NCT00001574 - A Pilot Study of 1H-Nuclear Magnetic Resonance Spectroscopic Imaging in Pediatric Patients With Primary and Metastatic Brain Tumors
Recruiting NCT02861898 - Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma Phase 1/Phase 2
Completed NCT00040573 - Safety and Tolerability Study of 131I-TM-601 to Treat Adult Patients With Recurrent Glioma. Phase 1/Phase 2
Active, not recruiting NCT04553757 - Seizure Control as a New Metric in Assessing Efficacy of Tumor Treatment in Patients With Low Grade Glioma
Recruiting NCT02754544 - Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors N/A
Recruiting NCT03216148 - 18F-FET PET in Childhood Brain Tumours Phase 2
Completed NCT00001171 - Evaluation of Factors in Human Brain Tumors N/A
Withdrawn NCT01413438 - Bevacizumab With or Without Surgery for Adult Glioblastomas Phase 2
Not yet recruiting NCT05516485 - Measuring Brain Tumor Consistency Using Magnetic Resonance Elastography N/A
Recruiting NCT02639325 - Tumor Related Epilepsy
Recruiting NCT02672995 - Fractionated Stereotactic Radiosurgery With Concurrent Bevacizumab for Brain Metastases: A Phase I Dose-escalation Trial Phase 1